Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 11/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | CSK | P41240 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5310133 | 1.00 | EPHB4 (0.38) | EPHB4KDRFGFR1MAPK14CSK | |
| SCHEMBL6417723 | 0.92 | CFD (0.34) | KDRMAPK14DYRK1B | |
| SCHEMBL6431698 | 0.87 | KDR (0.41) | KDR | |
| SCHEMBL5259529 | 0.86 | ACACB (0.36) | MAPK14 | |
| SCHEMBL5312681 | 0.86 | EPHB4 (0.37) | EPHB4KDRFGFR1MAPK14CSK | |
| SCHEMBL6415740 | 0.84 | KDR (0.33) | KDRMAPK14DYRK1B | |
| SCHEMBL5266372 | 0.83 | EPHB4 (0.44) | EPHB4KDRFGFR1MAPK14CSK | |
| SCHEMBL5317833 | 0.80 | KDR (0.40) | EPHB4KDRFGFR1MAPK14ACP1 | |
| SCHEMBL5314939 | 0.80 | KDR (0.40) | EPHB4KDRFGFR1MAPK14ACP1 | |
| SCHEMBL6421369 | 0.78 | EGLN2 (0.36) | MAPK14ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | claimed |
| EP-1765825-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004702-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | EPHB4 1901/4885KDR 218/4885FGFR1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.